¤	St. Marianna University, School of Medicine,	(Apr.1977~Mar.1983)
¤	Kagoshima University, PhD Course, Neuropharmacology	(Apr.1984~Mar.1988)
¤	Koyasan University, Master Course, Esoteric Buddhism	(Sep.2006~Aug.2008)

¤	Medical Doctor License (No.277850),	Jun.1983
¤	Certified Industrial Doctor (No.9011230), The Japan Medical Association;	Jan.1991 - 1996
¤	Ph.D. form Kagoshima University (No.252),	Mar. 1991
¤	Certified Toxicologist (No.62), Japanese Society of Toxicological Sciences,	Dec.1997
¤	FFPM from Faculty of Pharmaceutical Medicine of the Royal College of Physicians of the United Kingdom(No.1166),	Aug. 2000
¤	Certified Instructor for Clinical Pharmacologists (No.9810), Japanese Society of Clinical Pharmacology,	Apr. 2003
¤	M.A. from Koyasan University, Dept. of Esoteric Buddhism(No.339),	Sep. 2008

¤	President and CEO, Shin Nippon Biomedical Laboratories,Ltd.(Kagoshima, Japan),	Jan.1997 ~ present
¤	President, Shin Nippon Biomedical Laboratories, Ltd.	Jan.1991 ~ Jan.1997
¤	A member of the Board of Directors, Shin Nippon Biomedical Laboratories, Ltd.	Oct.1981 ~ Jan.1991
¤	CEO, SNBL Clinical Pharmacology Center, Inc. (MD, USA)	Oct.2004 ~ present
¤	CEO, SNBL Europe, Ltd. (UK)	Jul.1991 ~ present
¤	CEO, SNBL U.S.A., Ltd. (WA, USA)	Jul.1991 ~ present
¤	Chairman of the Board of Trustees, Medipolis Medical Research Foundation (Kagoshima, Japan),	Apr.2006 ~ present

¤	Adjunct Professor, YANTAI UNIVERSITY (China),	Nov.2011 ~ present
¤	Adjunct Professor, Tokyo Medical University,	Jul.2010 ~ present
¤	Adjunct Professor, Maryland University, Baltimore,	Jun.2009 ~ present
¤	Adjunct Professor, Koyasan University,	Apr.2008 ~ present
¤	Lecturer, Okayama University, Faculty of Medicine, Department of Public Health,	Apr.2006 ~ present
¤	Adjunct Clinical Professor, Kochi University, Medical School,	Jun.2003 ~ present
¤	Lecturer, Hiroshima University, Faculty of Medicine,	Apr.2003 ~ Mar.2006
¤	Adjunct Professor, Hokkaido University, Graduate School of Pharmaceutical Sciences,	Apr.2003 ~ Mar.2006
¤	Lecturer, Kanazawa University, School of Medicine,	Apr.1999 ~ present
¤	Adjunct Professor, St. Marianna School of Medicine,	Apr.1997 ~ present
¤	Lecturer, Kagoshima University, Faculty of Medicine,	Apr.1995 ~ present
¤	Adjunct Associate Professor, University of Rhode Island (USA), School of Pharmacology,	Apr.1994 ~ present
¤	Lecturer, Iwate University, Faculty of Agriculture, Department of Veterinary Medicine,	Apr.1993 ~ Mar.2002

¤	Strategic Planning Board Member, Kagoshima University,	2005
¤	A Weighted Member, Association for the Future of Biological Industry,	2005
¤	An Advisor for Venture Business, Ministry of Economy, Trade and Industry,	2003
¤	A Director of the Board, The Association for Preventive Medicine of Japan,	2002 - present
¤	A Member, Environmental Chemicals' Metabolism Study Group 2000 organized by the Ministry of Environment,	2000 - 2003
¤	A Member, Kagoshima City Information Network Committee;	1998 - 2002
¤	Nonofficial lecturer, Training session for intermediate officials of Kagoshima Municipal Offices,	1997 - 2002
¤	Chairman, Association of Contract Studies for Safety of Chemical Substances,	1996 - 1998

• American College of Toxicology (Full Member)
• American Society of Toxicology (Full Member)
• American College of Clinical Pharmacology (Full Member)
• The Association for Preventive Medicine of Japan (Director)
• The Japanese Society of Clinical Pharmacology (Councilor)
• The Japanese Society of Toxicological Sciences (Councilor)
• The Japanese Pharmacological Society (Councilor)

1. Introduction of Shin Nippon Biomedical Laboratories, Ltd. and Medipolis Ibusuki: The Liberal Democratic Party Head Quarters, Mar. 2009
2. Challenging Spirit of a Venture Founder: From a Small-Town Business to a Global Corporation, Cancer Therapy and Revitalization of Ibusuki City: Nikkei Lecture, Fukuoka, Feb. 2009
3. Successful Strides of Our Company Utilizing the Corporate Philosophy: 109th Japan Business Leader Conference, Tokyo, Dec. 2008
4. Dreams Come True: Visiting Lecture of a Business Leader, Kagoshima City Muregaoka Elementary School, Kagoshima, Nov. 2008
5. Translational Research, Preclinical Studies, and Clinical Research: Lecture for Graduate and Medical School Students, Kanazawa University, Kanazawa, Nov. 2008
6. Preclinical Studies, and Clinical Research: Lecture for Graduate School Students, Okayama University, Okayama, Nov. 2008
7. Path I Have Walked and Path I Will Walk: Cultural Conference, Kagoshima Chuo High School, Kagoshima, Nov. 2008
8. Dreams Come True: Visiting Lecture of a Business Leader, Kagoshima City Minami Elementary School, Kagoshima, Nov. 2008
9. Vision of Medipolis Ibusuki: Kagoshima University Clinical Pharmacology Department Seniors, Kagoshima, Oct. 2008
10. New Drug Development Business with Harvard University - New Antidepressant Drug: 8th Shinko Bio Symposium, Tokyo, Oct. 2008
11. How to Enjoy Work and Life - Teaching of Esoteric Buddhism: First Koyasan University Spiritual Care Seminar, Wakayama, Sep. 2008
12. Current Cancer Therapy in Kagoshima - Particle Beam Therapy: "Let's Think About Cancer Therapy in Kagoshima" Symposium, Kagoshima, Aug. 2008
13. Business Philosophy - Actual Practice: Koyasan University, Wakayama, May 2008
14. Special Lecture Regarding Particle Beam Therapy: Kagoshima Junshin Women's University, Kagoshima, Jan. 2008
15. Nomura Investment Forum 2006: Tokyo, Dec. 2006
16. Learning About Preclinical Studies, Clinical Research, and Translational Research: Okayama University Public Health Department, Okayama, Oct. 2006
17. Thought Leaders' Estimation: Future of Healthcare and Medicine in Japan: Shinko Bio Symposium, Tokyo, Oct. 2006
18. How to Thrive in the New Age - Criteria for Employees: Kagoshima Business Association, Educational Seminar, Kagoshima, Sep. 2006
19. Bioventures - Current Situation and Future Projection: Saitama Prefecture New Venture Support Center, Saitama, Jun. 2006
20. Establishing an "Only-One" Business from Kagoshima: Kagoshima Prefecture Chamber of Commerce and Industry, Mar. 2006
21. Likes and Dislikes: Nakagori Elementary School, Kagoshima, Feb. 2006
22. Current Trends and Future Outlook of University Bio-ventures: St. Marianna University, Research Center, Tokyo, Dec. 2005
23. Current Trends, Future Outlook for the CRO Industry: New York Pharma Forum, New York City, Oct. 2005
24. Establishing a Bio-venture Business and Experiences of an Industry-Academia Project: Tokyo University, School of Dentistry, Tokyo, Aug. 2005
25. Success Story: Buddhist Philosophies in Global Bioscience Business, University of Washington, May., 2005
26. Startup and Development of a Medical Business Venture: The Kansai Association for Venture and Entrepreneur Studies, Kobe, Feb., 2005.
27. Introduction of Shin Nippon Biomedical Laboratories, Ltd., Nomura BioConference 2005, Tokyo, Feb., 2005.
28. Experience of translational research by a University Bioventure: Kanazawa University, Department of Medicine, Ishikawa, Nov., 2004.
29. Birth of a new drug: Authorized NPO SASAEAI Medical Human Rights Center (COML) Patient School, Osaka, Apr., 2004.
30. Role of CRO in translational research: Millipore BioConference 2003, Tokyo, Jun., 2003.
31. Japanese regulatory environment: Forenap, XIV Colloque de Psychiatrie Biologique de Rouffach, CNS Drug Development, Rouffach, France, Oct. 2002.
32. Global role of CROs and SMOs in clinical research: The 12th International Conference on Pharmaceutical Medicine, Cancun, Mexico, May, 2002.
33. Introduction of Shin Nippon Biomedical Laboratories, Ltd., Kansai BioConference in Kobe, Kobe, Mar., 2002.
34. Introduction of Shin Nippon Biomedical Laboratories, Ltd., Nomura BioConference 2002, Tokyo, Mar., 2002.
35. The CRO and SMO revolution: DIA 4th Annual Workshop; Philadelphia, U.S.A., Feb., 2002.
36. The state of new drug development observed by a CRO engaged in drug development business: Cancer Molecular Target Chemotherapy Niseko Workshop, Hokkaido, Aug., 2001.
37. A new century in Japan: After the CRO and SMO revolution: DIA Annual EuroMeeting, Barcelona, Spain, Mar., 2001.
38. A new century in Japan: After the CRO and SMO revolution: DIA 3rd Annual Workshop, Philadelphia, U.S.A., Feb., 2001.
39. Drug development and regulatory issues in Japan: Japan-America Society, Seattle, U.S.A., Sep., 2000.
40. Japanese specifics: The CRO and SMO revolution: DIA 36th Annual Meeting, San Diego, U.S.A., Jun., 2000.
41. Japanese specifics: An introduction to the regulatory environment: Japan's new GCP: From the hospital's side: DIA Workshop 4, Nice, France, Mar., 2000.
42. Japan's new GCP: Can hospitals adapt? GCP as applied in Japanese hospitals: DIA: Japan Pharmaceutical Development, Registration and the Culture that Supports It, Philadelphia, U.S.A., Feb., 2000.
43. Today's typical Japanese company management: 1999 Training session for intermediate officials of Kagoshima municipal offices, Kagoshima, Nov., 1999.
44. Regulatory submission in Japan: Recent trends in regulatory submission: DIA 35th Annual Meeting, Baltimore, U.S.A., Jun., 1999.
45. Japan's new GCP: Can hospitals adapt?: DIA 35th Annual Meeting, Baltimore, U.S.A., Jun., 1999.
46. What a CRO in Japan can do for Western pharmaceutical companies during pre-clinical and registration phases: DIA: Japan Pharmaceutical Development, Registration and the Culture That Supported It, Philadelphia, U.S.A., Feb., 1999.
47. Recent Changes That Have Been Made on Basic Pre-Clinical Packages to Support Entry to Clinical Development Stages and Registration in Japan: DIA: Japan Pharmaceutical Development, Registration and the Culture That Supported It, Philadelphia, U.S.A., Feb., 1999.
48. East-West development: The acceptability of Phase I clinical data in Japan: AGAH Annual Meeting 1999, Heidelberg, Germany, Feb., 1999.
49. Today's typical Japanese company management: 1998 Training session for intermediate officials of Kagoshima municipal offices, Kagoshima, Nov., 1998.
50. Understanding the usability and acceptance of foreign clinical data in Japan: 1999 AGAH Annual Meeting, Heidelberg, Germany, Feb., 1999.
51. Communication in the sponsor-CRO relationship: The 13th SQA Annual Meeting, Seattle, U.S.A., Oct., 1997.
52. Study on relevance between side effects observed in Phase I clinical trials and non-clinical study data: Japan Pharmaceutical Manufacturers Association Lecture Meeting, Tokyo, Sep., 1997.
53. Communication and dialogue between drug regulatory authorities and pharmaceutical industry: Symposium 1 in Opening Ceremony Conference on Pharmaceutical Medicine Post Marketing Surveillance, The 9th International Conference on Pharmaceutical Medicine; Stockholm, Sweden, Jun., 1996.
54. Achieving registration of pharmaceuticals in Japan: Management Forum, Copenhagen, Denmark, Feb., 1996.
55. Achieving registration of pharmaceuticals in Japan: Management Forum, London, U.K, Nov., 1995.
56. Biotechnology Industry Organization Conference (BIO 95), San Francisco, U.S.A., May, 1995.
57. The clinical trials environment in Japan: Management Forum, London, U.K., Feb., 1995.
58. Lecture at a training session for new section chiefs of Kagoshima Prefecture government office: Kagoshima Prefectural Culture Center, Kagoshima, Nov., 1994.
59. Evaluation of toxicity of agricultural chemicals and understanding of health injuries: Symposium on Agricultural Chemical Poisoning, Kagoshima, Feb., 1994.
60. Registration of pharmaceuticals in Japan: Focus Academy Executive Briefing, Neuss, Germany, Jun., 1993.
61. Industrial hygiene in enterprises: Minami Kyushu Chemical Engineering Meeting, Miyazaki, Oct., 1992.

• 173 publications (as of May, 2009)

• 148 presentations (as of May, 2009)